ECSP055574A - Uso de derivados de tio-oxindol en el tratamiento de condiciones relacionadas con hormonas. - Google Patents

Uso de derivados de tio-oxindol en el tratamiento de condiciones relacionadas con hormonas.

Info

Publication number
ECSP055574A
ECSP055574A EC2005005574A ECSP055574A ECSP055574A EC SP055574 A ECSP055574 A EC SP055574A EC 2005005574 A EC2005005574 A EC 2005005574A EC SP055574 A ECSP055574 A EC SP055574A EC SP055574 A ECSP055574 A EC SP055574A
Authority
EC
Ecuador
Prior art keywords
formula
thio
hormones
treatment
administration
Prior art date
Application number
EC2005005574A
Other languages
English (en)
Inventor
Andrew Fensome
Gary Grubb
Diane Deborah Harrison
Richarg Craing Winneker
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP055574A publication Critical patent/ECSP055574A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona métodos para inducir contracepción, el cual incluye la administración a una fémina de una composición que contiene un compuesto de fórmula I o tautómeros del mismo, en un régimen el cual involucra la administración de uno o más de un modulador del receptor de estrógenos selectivo, donde la fórmula I y donde R1-R5 y Q1 son definidos como se describe aquí. Se describen métodos para proveer terapia de re-emplazo hormonal y para tratar carcinomas, sangramiento disfuncional, leiomiomata uterino, endometriosis y síndrome del ovario poliquístico, los cuales incluyen la administración de un compuesto de fórmula I y un modulador del receptor de estrógenos selectivo.
EC2005005574A 2002-06-25 2005-01-25 Uso de derivados de tio-oxindol en el tratamiento de condiciones relacionadas con hormonas. ECSP055574A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39182602P 2002-06-25 2002-06-25

Publications (1)

Publication Number Publication Date
ECSP055574A true ECSP055574A (es) 2005-04-18

Family

ID=30000758

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005574A ECSP055574A (es) 2002-06-25 2005-01-25 Uso de derivados de tio-oxindol en el tratamiento de condiciones relacionadas con hormonas.

Country Status (17)

Country Link
US (3) US7488734B2 (es)
EP (1) EP1531806A4 (es)
JP (1) JP2005535623A (es)
CN (1) CN1662234A (es)
AR (1) AR040339A1 (es)
AU (1) AU2003245637A1 (es)
BR (1) BR0312054A (es)
CA (1) CA2489813A1 (es)
CR (1) CR7610A (es)
EC (1) ECSP055574A (es)
IL (1) IL165395A0 (es)
MX (1) MXPA04012419A (es)
NO (1) NO20045217L (es)
RU (1) RU2005101635A (es)
TW (1) TW200407124A (es)
WO (1) WO2004000225A2 (es)
ZA (1) ZA200410409B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
RU2005101635A (ru) * 2002-06-25 2005-08-10 Уайт (Us) Применение производных тиооксиндола в терапии гормонозависимых состояний
JP2007532548A (ja) * 2004-04-07 2007-11-15 ワイス バゼドキシフェンアセテートの結晶質多形体
WO2005100316A1 (en) * 2004-04-07 2005-10-27 Wyeth Crystalline polymorph of a bazedoxifene acetate
ATE413398T1 (de) 2004-04-08 2008-11-15 Wyeth Corp Thioamidderivate als progesteronrezeptormodulatoren
ATE409699T1 (de) * 2004-04-08 2008-10-15 Wyeth Corp Verfahren zur minimierung von thioamidverunreinigungen
WO2005120432A1 (en) * 2004-06-07 2005-12-22 Duramed Pharmaceuticals, Inc. Dispenser for progestin used for acute and maintenance treatment of dub
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
AR056968A1 (es) 2005-04-11 2007-11-07 Xenon Pharmaceuticals Inc Compuestos espiro-oxindol y composiciones farmacéuticas
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
WO2008060789A2 (en) 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
BRPI0819571A2 (pt) * 2007-12-20 2019-09-24 Teva Womenss Health Inc "método para contracepção de emergência, pacote farmacêutico para contracepção de emergência e composição farmacêutica"
JO3032B1 (ar) 2008-10-17 2016-09-05 Xenon Pharmaceuticals Inc مركبات سبيرو – اوكسندول وإستعمالاتها كعوامل علاجية.
CA2741024A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
WO2011029782A1 (en) * 2009-09-11 2011-03-17 Bayer Schering Pharma Aktiengesellschaft Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs
KR20120099429A (ko) 2009-10-14 2012-09-10 제논 파마슈티칼스 인크. 스피로-옥스인돌 화합물의 합성 방법
WO2011106729A2 (en) 2010-02-26 2011-09-01 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
RS56042B1 (sr) 2010-06-10 2017-09-29 Seragon Pharmaceuticals Inc Modulatori estrogenih receptora i njihove upotrebe
WO2013090829A1 (en) 2011-12-14 2013-06-20 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5461065A (en) * 1993-10-15 1995-10-24 Eli Lilly And Company Methods for inhibiting endometriosis
DE4335876A1 (de) 1993-10-17 1995-04-20 Schering Ag Kombination von Progesteronantagonisten und Antiöstrogenen mit partialer agonistischer Wirkung für die Hormonsubstitutions-Therapie für peri- und postmenopausale Frauen
US5446053A (en) * 1993-12-21 1995-08-29 Eli Lilly And Company Methods of inhibiting dysfunctional uterine bleeding
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
US6653297B1 (en) * 1997-07-03 2003-11-25 Medical College Of Hampton Roads Control of selective estrogen receptor modulators
US6326392B1 (en) * 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
IL142598A0 (en) * 1998-10-23 2002-03-10 Aventis Pharma Gmbh Preparations for topical application of substances having antiandrogenic effect
US6331562B1 (en) * 1998-12-30 2001-12-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
MXPA01006742A (es) 1998-12-31 2004-04-21 Sugen Inc Compuestos 3-heteroarilidenil-2-indolinona para modular la actividad de la quinasa de proteina y para utilizarse en la quimioterapia de cancer.
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6355648B1 (en) * 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
EP1206761B1 (en) 1999-08-26 2007-10-03 Automotive Systems Laboratory Inc. Magnetic sensor
US6566372B1 (en) * 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US20010034340A1 (en) * 2000-03-20 2001-10-25 American Home Products Corporation Hormone replacement therapy
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
CZ2003514A3 (cs) * 2000-08-23 2003-10-15 Akzo Nobel N. V. Fluorenové deriváty a jejich analogy
RU2005101635A (ru) 2002-06-25 2005-08-10 Уайт (Us) Применение производных тиооксиндола в терапии гормонозависимых состояний
US7268149B2 (en) 2002-06-25 2007-09-11 Wyeth Cyclothiocarbamate derivatives as progesterone receptor modulators and methods of treating skin disorders
RU2005101638A (ru) 2002-06-25 2006-01-20 Уайт (Us) Использование циклокарбаматных производных для лечения гормонзависимых состояний
KR20050012831A (ko) 2002-06-25 2005-02-02 와이어쓰 피부 질환을 치료하는 데 있어서의 티오-옥스인돌유도체의 용도

Also Published As

Publication number Publication date
WO2004000225A3 (en) 2004-06-10
AR040339A1 (es) 2005-03-30
US20120220558A1 (en) 2012-08-30
EP1531806A4 (en) 2005-09-21
US8242098B2 (en) 2012-08-14
JP2005535623A (ja) 2005-11-24
TW200407124A (en) 2004-05-16
CR7610A (es) 2006-05-29
US7488734B2 (en) 2009-02-10
MXPA04012419A (es) 2005-04-19
CA2489813A1 (en) 2003-12-31
IL165395A0 (en) 2006-01-15
ZA200410409B (en) 2006-05-31
US20090099223A1 (en) 2009-04-16
RU2005101635A (ru) 2005-08-10
NO20045217L (no) 2005-03-15
EP1531806A2 (en) 2005-05-25
WO2004000225A2 (en) 2003-12-31
AU2003245637A1 (en) 2004-01-06
US20040002535A1 (en) 2004-01-01
CN1662234A (zh) 2005-08-31
BR0312054A (pt) 2005-10-18

Similar Documents

Publication Publication Date Title
ECSP055574A (es) Uso de derivados de tio-oxindol en el tratamiento de condiciones relacionadas con hormonas.
ECSP055576A (es) Uso de derivados de ciclotiocarbamato en el tratamiento de las condiciones relacionadas con hormonas
CL2012000166A1 (es) Compuesto (11beta,17beta)-17-hidroxi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona; y su uso para el tratamiento y/o la prevencion de fibroides uterinos, endometriosis, sangrados menstruales severos, meningiomas, cancer de mama hormonodependiente y de trastornos asociados a la menopausia, entre otros.
NI201000183A (es) Regímenes de dosificación de antiprogestina.
PE20211588A1 (es) Compuestos y sus usos para aliviar sintomas asociados a la menopausia
HN2008000621A (es) Metodo para la anticopcepcion hormonal preventiva bajo demanda
UY30109A1 (es) Formas farmacológicas en forma de película para usar en la cavidad bucal (obleas)
ECSP066999A (es) Envase farmacéutico para anticoncepción hormonal de régimen extendido flexible
PE20020348A1 (es) Exemestano como agente quimiopreventivo
DOP2006000110A (es) Composición farmaceútica que contiene gestágenos y/o estrógenos y 5-metil-(6s)-tetrahidrofolato
WO2007016385A3 (en) Use of substituted 5-amino-1h-pyrrole-2-carbonitrile derivatives as progesterone receptor modulators
CR10617A (es) Derivados de oxazolidona como moduladores pr
ECSP078043A (es) Derivados de benzofurarona como moduladores no esteroides de receptores de progesterona
PA8771801A1 (es) Heterociclos sulfonilados utiles para la modulacion del receptor de progesterona
UY28334A1 (es) Composicion que comprende antagonistas de receptores de progesterona y antiestrógenos puros para la profilaxis y el tratamiento de enfermedades dependientes de hormonas.
CY1121190T1 (el) Δοσολογικη μορφη ανταγωνιστη υποδοχεα προγεστερονης
CR9598A (es) Moduladores no esteroides de receptor de progesterona
PA8633601A1 (es) Profarmacos de esteroides con accion androgenica
ECSP109872A (es) Estratrienos 8-beta-sustituidos como estrógenos de acción selectiva
DOP2006000147A (es) Uso de modulares no esteroides de receptores de progesterona.
UY26665A1 (es) Estratrienos sustituidos como estrógenos selectivamente activos
MX2009009515A (es) Cianopirrol sulfonamidas utiles para la modulacion del receptor de progesterona.
AR036227A1 (es) USO DE LIGANDOS SELECTIVOS PARA ERa PARA REGULAR LA FERTILIDAD.
AR023854A1 (es) Uso de derivados de indolina y equipo farmaceutico para regimenes ciclicos
UY26967A1 (es) Derivados 8beta-sustituidos de 11beta-pentil y 11beta-hexil-estra-1,3,5(10)-trieno.-